BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22078546)

  • 1. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
    Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
    Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Population pharmacokinetics applied to optimising cisplatin doses in cancer patients].
    Ramón-López A; Escudero-Ortiz V; Carbonell V; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(5):392-402. PubMed ID: 22402361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):137-45. PubMed ID: 16515668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
    Lin NM; Zeng S; Ma SL; Fan Y; Zhong HJ; Fang L
    Acta Pharmacol Sin; 2004 Dec; 25(12):1584-9. PubMed ID: 15569401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
    Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
    Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
    Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
    Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
    Masumori N; Kunishima Y; Hirobe M; Takeuchi M; Takayanagi A; Tsukamoto T; Itoh T
    Jpn J Clin Oncol; 2008 Mar; 38(3):182-5. PubMed ID: 18270381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
    Jiang X; Galettis P; Links M; Mitchell PL; McLachlan AJ
    Br J Clin Pharmacol; 2008 Mar; 65(3):326-33. PubMed ID: 17961191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
    Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
    Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
    Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
    Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
    Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
    Yilmaz B; Kadioğlu YY; Aksoy Y
    Anal Biochem; 2004 Sep; 332(2):234-7. PubMed ID: 15325290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.